Phase I safety and pharmacokinetics of ADU-1604, an anti-CTLA-4 antibody, in adults with metastatic melanoma

被引：0
|
作者：
Hendriks, M. [1 ]
de Cock, E. [1 ]
Maplestone, K. [1 ]
Namini, H. [1 ]
van Elsas, A. [1 ]
机构：
[1] Aduro Biotech Europe, Oss, Netherlands
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
107TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Characterization of a novel differentiated anti-CTLA-4 antibody (ADU-1604) in vitro and in vivo
    Hendriks, Maaike
    Kreijtz, Joost
    Vink, Paul
    Hulsik, David Lutje
    Lodewijks, Imke
    Bertens, Astrid
    van de Crommert, Jos
    Habraken, Maurice
    Janssen, Wout
    Stammen-Vogelzang, Judith
    Deng, Weiwen
    Glickman, Laura Hix
    Leong, Meredith
    McWhirter, Sarah
    Dubensky, Thomas
    van Eenennaam, Hans
    van Elsas, Andrea
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [2] Assessment of pharmacology and toxicology of anti-CTLA-4 antibody (ADU-1604) in nonhuman primates and evaluation of local anti-CTLA-4 application
    Hendriks, Maaike
    Kreijtz, Joost
    Vink, Paul
    Hulsik, David Lutje
    Lodewijks, Imke
    Bertens, Astrid
    van de Crommert, Jos
    Habraken, Maurice
    Janssen, Wout
    Stammen-Vogelzang, Judith
    Gardner, Olivia
    Deng, Weiwen
    Leong, Meredith
    McWhirter, Sarah
    van Eenennaam, Hans
    van Elsas, Andrea
    [J]. CANCER RESEARCH, 2018, 78 (13)
  • [3] Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
    Lipson, Evan J.
    Drake, Charles G.
    [J]. CLINICAL CANCER RESEARCH, 2011, 17 (22) : 6958 - 6962
  • [4] ADU-1604, a novel CTLA-4 blocking antibody, to modulate pharmacodynamic markers in patients with PD1 relapse/refractory melanoma
    De Velasco, Guillermo
    Rutkowski, Piotr
    Di Giacomo, Anna Maria
    Arance, Ana Maria
    Robert, Caroline
    Chiarion-Sileni, Vanna
    Marquez-Rodas, Ivan
    Kundapur, Jessica
    Villaudy, Julien
    van Eenennaam, Hans
    Lassouw-Polman, Laura
    Eggermont, Alexander M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma
    Maker, AV
    Yang, JC
    Sherry, RM
    Topalian, SL
    Kannula, US
    Royal, RE
    Hughes, M
    Yellin, MJ
    Haworth, LR
    Levy, C
    Allen, T
    Mavroukakis, SA
    Attia, P
    Rosenberg, SA
    [J]. JOURNAL OF IMMUNOTHERAPY, 2006, 29 (04) : 455 - 463
  • [6] Anti-CTLA-4 Antibody Adjuvant Therapy in Melanoma
    Eggermont, Alexander M. M.
    Testori, Alessandro
    Maio, Michele
    Robert, Caroline
    [J]. SEMINARS IN ONCOLOGY, 2010, 37 (05) : 455 - 459
  • [7] Evaluating the safety of anti-CTLA-4 therapy in the elderly with unresectable melanoma
    Chandra, Sunandana
    Madden, Kathleen M.
    Kannan, Rajni
    Pavlick, Anna C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [8] Anti-CTLA-4 antibodies A major therapeutic advance in metastatic melanoma treatment
    Robert, Caroline
    Mateus, Christine
    [J]. M S-MEDECINE SCIENCES, 2011, 27 (10): : 850 - 858
  • [9] Sarcoidosis in a Patient with Metastatic Melanoma Sequentially Treated with Anti-CTLA-4 Monoclonal Antibody and Selective BRAF Inhibitor
    Wilgenhof, Sofie
    Morlion, Veerle
    Seghers, Amelie Clementine
    Du Four, Stephanie
    Vanderlinden, Esther
    Hanon, Shane
    Vandenbroucke, Frederik
    Everaert, Hendrik
    Neyns, Bart
    [J]. ANTICANCER RESEARCH, 2012, 32 (04) : 1355 - 1359
  • [10] RETRACTED: Combination Anti-CTLA-4 and Anti-RANKL in Metastatic Melanoma (Retracted Article)
    Smyth, Mark J.
    Yagita, Hideo
    McArthur, Grant A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (12) : E104 - E106
12345